Results 151 to 160 of about 21,169 (256)

Cutting‐edge advances in bicyclic peptide‐based radiotracers for cancer imaging and theranostics

VIEW, Volume 7, Issue 2, April 2026.
Bicyclic peptides, a burgeoning subset of bicyclic macrocycles, are characterized by two loops stabilized through three linkages of the central chemical scaffolds. As an immense potential platform for radiotracers development, bicyclic peptide‐based radiotracers have yielded encouraging results in preclinical and clinical trial studies.
Hengyi Ou, Xiaobo Wang, Fei Kang
wiley   +1 more source

Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 199-206, April 2026.
ABSTRACT Objective 177Lu‐PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration‐resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu‐PSMA‐RLT from two university ...
Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon‐iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee   +6 more
wiley   +1 more source

Isolated pulmonary metastasis of prostate adenocarcinoma detected by ProstaScint scan [PDF]

, 2008
Scholarly project (M.S.)
Boyer, Brendan Patrick
core   +1 more source

Diagnostic accuracy and outcomes of lymph node staging in intermediate‐risk prostate cancer

BJU International, Volume 137, Issue 4, Page 667-676, April 2026.
Objective To evaluate the diagnostic performance of different staging modalities and oncological outcomes in patients with intermediate‐risk (IR) prostate cancer (PCa) undergoing radical prostatectomy (RP) with pelvic lymph node dissection (PLND).
Christopher Kniep, Tobias Maurer, Ben Frederik Hartwieg, Philipp Mandel, Mike Wenzel, Fabian Falkenbach, Kristian Krpina, Lars Budäus, Alexander Haese, Georg Salomon, Thomas Steuber, Markus Graefen, Derya Tilki, Felix Preisser   +13 more
wiley   +1 more source

From mechanism to phenotype: What fits in a basket trial

Epilepsia, Volume 67, Issue 4, Page 1573-1581, April 2026.
Kette D. Valente
wiley   +1 more source

Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro. [PDF]

Int J Mol Sci, 2023
Kuzmanov A, Salemi S, Schmid FA, Burger IA, Eberli D, Kranzbühler B.   +5 more
europepmc   +1 more source

Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer

Cancer Imaging
Background Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of ...
Caroline Burgard, Florian Rosar, Elena Larsen, Fadi Khreish, Johannes Linxweiler, Robert J. Marlowe, Andrea Schaefer-Schuler, Stephan Maus, Sven Petto, Mark Bartholomä, Samer Ezziddin   +10 more
doaj   +1 more source

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer. [PDF]

EJNMMI Res, 2023
Wang H, Remke M, Horn T, Schwamborn K, Chen Y, Steiger K, Weichert W, Wester HJ, Schottelius M, Weber WA, Eiber M.   +10 more
europepmc   +1 more source

Prostate-Specific Membrane Antigen (PSMA) Expression in The Neovasculature of High Grade Gliomas (Histopathological and Immunohistochemical Study). [PDF]

Asian Pac J Cancer Prev, 2023
Abdel Maguid MS, Saad El Dine MG, Gabal SM, Abou Fandoud SM.   +3 more
europepmc   +1 more source

Prostate-specific membrane antigen (PSMA; FOLH1; GCPII); CD3 [PDF]

Science-Business eXchange, 2013
openaire   +1 more source